High-Throughput Screening (HTS) Market size was over USD 23.33 billion in 2024 and is likely to exceed USD 88.41 billion by the end of 2037, growing at over 10.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of high-throughput screening is evaluated at USD 25.35 billion. The growth of the market can be attributed to the growing demand for stem cell therapy. The increased incidence of chronic illnesses across the globe is rising the need for stem cell treatment. Further, researchers frequently utilize high-throughput screening (HTS) of stem cells to better understand the fundamental mechanisms governing stem cell destiny, which is also expected to add to the market growth. Over 20% of New York individuals have a chronic illness, and more than 22% of all hospitalizations in the state are brought on by these conditions.
In addition to these, factors that are believed to fuel the market growth of high-throughput screening (HTS) include the increasing number of drug targets being employed for screening. The identification of a novel therapeutic target is frequently the initial step in the research and development of medications. For instance, in drug development, phenotypic screening is a method for finding compounds that can change a cell's phenotype. Additionally, the increasing investments by the government and research institutes to develop new products are predicted to present the potential for market expansion over the projected period.
Growth Drivers
Growing Demand for Drugs– On account of the increasing prevalence of chronic disorders across the globe has increased the demand for medicines for treatment. Further, the growing use of HTS for the drug development process is estimated to drive market growth. The number of drug users worldwide is expected to increase by over 10% by 2030.
Rising Geriatric Population – Owing to a weak immune system elderly population is more prone to various diseases such as dementia, high blood pressure, and diabetes, which is estimated to drive market growth. As of 2021, the elderly population in India is predicted to increase by over 9%.
Increasing Health Spending – Increased government programs and investments in medication research, are anticipated to drive the market growth According to the most recent expenditure data, in 2020, health spending in the US rose by over 9%.
Growing Pharmaceutical and Biotechnology Sectors – It is expected that the growing launch of new and advanced drugs, and strong investment in the biotech and pharmaceutical industries, are anticipated to drive market growth. According to estimates, the biotechnology sector in India has grown to a value of over USD 80 billion in 2022.
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
10.7% |
Base Year Market Size (2024) |
USD 23.33 billion |
Forecast Year Market Size (2037) |
USD 88.41 billion |
Regional Scope |
|
Products & Services (Consumables, Instruments, Software, Services)
The global high-throughput screening (HTS) market is segmented and analyzed for demand and supply by-products into consumables, instruments, software, and services. Out of the four products, the consumables segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing demand for new and advanced drugs. The adoption of HTS for developing new drugs is anticipated to create numerous opportunities for the growth of the segment. For instance, microplates, pipette tips, and assay plates are consumables that are essential to the HTS workflow. In addition, improvements in HTS technology that enable more intricate and varied screening trials rises the demand for consumables. Furthermore, the need for specialized consumables will probably increase as HTS technologies develop further. By 2026, over 200 new medications are anticipated to be released across the globe.
End-user (Pharmaceutical & Biotechnology Firms, Academia & Research Institutes)
The global high-throughput screening (HTS) market is also segmented and analyzed for demand and supply by end-user into pharmaceutical & biotechnology firms, academia & research institutes, and contract research organizations. Amongst these three segments, the pharmaceutical & biotechnology firms segment is expected to garner a significant share. The growth can be attributed to the increasing creation of new compounds to cure many chronic diseases. High-throughput screening (HTS) is widely used in the pharmaceutical and biotechnology industries to find new drugs. Further, the drug development process has been transformed by HTS technology, which allows scientists to quickly screen millions of molecules. As a result, several novel medications have been created to treat a variety of illnesses and ailments, such as cancer, cardiovascular, and infectious diseases. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
By Products & Services |
|
By Technology |
|
By Application |
|
By End User |
|
North American Market Forecast
The North American high-throughput screening (HTS) market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the growing pharmaceutical industry owing to the rise in chronic illnesses in the region. The creation and manufacture of new and unique drugs for a variety of life-threatening illnesses such as cancer, cardiovascular disorders, metabolic disorders, immunological disorders, and neurological disorders are a focus of both large and small pharmaceutical businesses in the region. This as result will rise the demand for high throughput screening as it is required for screening novel chemical entities with more efficiency. Further, the rising investment in R&D by pharmaceutical and biotechnology, and increasing technological developments in high-throughput screening (HTS), are also anticipated to contribute to the market growth in the region. Almost half of adult Americans suffer from chronic illnesses, which accounts for over 60% of all fatalities in the United States.
APAC Market Statistics
The Asian Pacific high-throughput screening (HTS) market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the growing cases of chronic diseases in the region. The main causes of mortality and disability in the area are chronic illnesses including diabetes, cancer, heart disease like heart attack, and many more, caused by the growing usage of tobacco and being around smoke. The usage of medicine is one of the most popular techniques to manage chronic illness. The use of HTS in the drug development process allows for the subsequent identification of candidates for the treatment of chronic illnesses including cancer, HIV, and cardiovascular ailments, which is anticipated to contribute to the market growth in the region. In addition, the region's growing healthcare industry and adoption of innovative technology to raise the quality of medication, are also anticipated to boost the market growth during the forecast period. By 2045 India is predicted to have over 130 million people with diabetes.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the growing technologically advanced products in the high throughput screening. For instance, the pharmaceutical and biotech sectors have a significant interest in using AI in HTS. The majority of the biggest biopharmaceutical firms in the region are working together to build AI platforms for enhancing the research capacity of immuno-oncology medications, metabolic disease medicines, cancer treatments, and many other therapeutic targets. In addition, high-throughput screening is also in higher demand since it is necessary to screen novel chemical entities, which in turn is anticipated to contribute to the market growth in the region.
PerkinElmer Inc. introduced EnVision Nexus system, which enables researchers to screen millions of samples with greater accuracy, speed, and sensitivity. Further, it is developed for demanding high-throughput screening (HTS) applications and to speed up drug development efforts.
Thermo Fisher Scientific teamed up with Celltrio to introduce a fully automated cell culture system. The collaboration will fill a major need in the market for high-throughput automated cell line culture and maintenance.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?